Cardlytics, Inc. (NASDAQ:CDLX) Short Interest Update

Cardlytics, Inc. (NASDAQ:CDLX) saw a large decline in short interest during the month of October. As of October 15th, there was short interest totalling 7,610,000 shares, a decline of 8.2% from the September 30th total of 8,290,000 shares. Based on an average trading volume of 1,200,000 shares, the short-interest ratio is presently 6.3 days.

Cardlytics Stock Up 4.1 %

CDLX traded up $0.17 during trading hours on Thursday, hitting $4.31. 487,043 shares of the company’s stock were exchanged, compared to its average volume of 1,231,100. The company has a quick ratio of 1.77, a current ratio of 1.77 and a debt-to-equity ratio of 1.01. Cardlytics has a 1-year low of $2.89 and a 1-year high of $20.52. The stock’s 50-day moving average is $3.62 and its two-hundred day moving average is $7.05. The stock has a market cap of $210.25 million, a price-to-earnings ratio of -0.98 and a beta of 1.67.

Cardlytics (NASDAQ:CDLX) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.12. The company had revenue of $69.64 million during the quarter, compared to the consensus estimate of $75.39 million. Cardlytics had a negative net margin of 50.21% and a negative return on equity of 17.96%. The company’s quarterly revenue was down 9.2% on a year-over-year basis. During the same period in the prior year, the business posted ($0.57) EPS. Sell-side analysts predict that Cardlytics will post -1.72 earnings per share for the current fiscal year.

Insider Buying and Selling at Cardlytics

In related news, Director Scott A. Hill bought 40,000 shares of the business’s stock in a transaction on Monday, August 12th. The shares were purchased at an average price of $3.58 per share, with a total value of $143,200.00. Following the completion of the purchase, the director now owns 40,000 shares of the company’s stock, valued at $143,200. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, CEO Amit Gupta sold 22,607 shares of Cardlytics stock in a transaction on Thursday, October 24th. The shares were sold at an average price of $3.85, for a total transaction of $87,036.95. Following the transaction, the chief executive officer now directly owns 178,519 shares of the company’s stock, valued at $687,298.15. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Scott A. Hill acquired 40,000 shares of the stock in a transaction that occurred on Monday, August 12th. The stock was purchased at an average price of $3.58 per share, with a total value of $143,200.00. Following the transaction, the director now owns 40,000 shares in the company, valued at $143,200. The disclosure for this purchase can be found here. In the last 90 days, insiders sold 43,573 shares of company stock worth $151,612. Insiders own 4.40% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Creative Planning boosted its holdings in shares of Cardlytics by 35.4% in the 3rd quarter. Creative Planning now owns 29,537 shares of the company’s stock valued at $95,000 after buying an additional 7,721 shares during the last quarter. SG Americas Securities LLC acquired a new stake in Cardlytics in the third quarter valued at $45,000. Marshall Wace LLP grew its position in shares of Cardlytics by 6.8% in the 2nd quarter. Marshall Wace LLP now owns 814,281 shares of the company’s stock valued at $6,685,000 after acquiring an additional 52,081 shares during the period. XTX Topco Ltd bought a new position in shares of Cardlytics in the 2nd quarter valued at about $107,000. Finally, Pekin Hardy Strauss Inc. acquired a new position in shares of Cardlytics during the 2nd quarter worth about $243,000. 68.10% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on CDLX shares. Northland Capmk lowered Cardlytics from a “strong-buy” rating to a “hold” rating in a research report on Friday, August 16th. Craig Hallum downgraded shares of Cardlytics from a “buy” rating to a “hold” rating in a research report on Thursday, August 8th. Lake Street Capital cut shares of Cardlytics from a “buy” rating to a “hold” rating and cut their price objective for the company from $18.00 to $5.00 in a research report on Thursday, August 8th. Northland Securities cut Cardlytics from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $7.00 to $5.00 in a report on Friday, August 16th. Finally, Evercore ISI assumed coverage on Cardlytics in a research note on Friday, October 11th. They issued an “in-line” rating and a $4.00 price target on the stock. One research analyst has rated the stock with a sell rating and six have given a hold rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $6.92.

About Cardlytics

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.